AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$SIBN

FRANCIS LAURA sold $523K of SIBN (indirect holdings)

FRANCIS LAURA (Chief Executive Officer) sold 25,972 indirectly-held shares of SI-BONE, Inc. (SIBN) at $20.12 ($0.52M total) on 2026-08-24 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · FRANCIS LAURA
Published Aug 26, 2026, 11:06 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 26, 2026, 11:22 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$SIBN
Bearish
medium confidence
Mentioned
$SIBN
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SIBNBearishLow
01

Why it matters

The CEO's sale reduces insider ownership, which some investors view as a bearish signal.

02

Market read

While the transaction size is modest, insider sales by CEOs are closely watched and can influence short-term trading sentiment.

03

What to watch

Potential upcoming clinical data releases could offset sell pressure.

Relevance 4/10Novelty 5/10Timing: post-market filing on 2026-08-24

Background

Form 4 filings disclose insider transactions and are primary sources of new corporate information.

Company-level read

Ticker impact

$SIBNBearishMedium confidence
Context

CEO Laura Francis sold 25,972 shares of SI-BONE at $20.12 via a 10b5-1 plan, reducing her stake to 291,491 shares.

Expected impact

modest short-term price dip

Evidence & confidence

A $523K sale by the CEO is material for a mid‑cap biotech, but the amount is modest relative to market cap.

Market effects

Sector

May prompt scrutiny of insider activity in the orthopedic biotech sector.

Regional

Limited to US biotech investors.

Global

Minimal global effect.

Counterpoint

What could challenge this read

The sale could be routine under a 10b5-1 plan, not reflecting negative outlook.

Key entities

  • Company
    SI-BONE, Inc.

    Medical device company focused on orthopedic solutions.

  • Executive
    Laura Francis

    Chief Executive Officer of SI-BONE.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

SIBN insider trading history →

Related articles

$SIBNHigh

Healthcare Stocks Move Higher: SIBN Rallies 18%, NBIX Gains 16%, RMTI Climbs 16%, PTCT Up 13%

Healthcare stocks rose due to earnings reports and corporate actions. SI-BONE (SIBN) reported Q3 revenue of $55.7M, a 14.5% increase, and reaffirmed its full-year outlook. Neurocrine Biosciences (NBIX) reported Q3 revenue of $1.122B, up 41.1%. Rockwell Medical (RMTI) agreed to acquire Vantive's hemodialysis assets. PTC Therapeutics (PTCT) authorized a $500M share repurchase program.

rttnews.com
$SIBNMed

SI-BONE (SIBN) Q3 2026 Earnings Call Transcript

SI-BONE (SIBN) reported Q3 2026 earnings, highlighting 27% international revenue growth and 32% adjusted EBITDA increase. The company launched iFuse Granite Onyx, expanding its market to 650,000 procedures and $5B opportunity. Onyx targets spinal fusion failure points, with early demand exceeding expectations. New DRGs and reimbursement enhancements support growth. The company expects 20%+ revenue growth in Q4 2026.

finance.yahoo.com
$SIBNMed

SiBone Q3 Earnings Call Highlights

SiBone (SIBN) reported Q3 earnings, highlighting strong demand for its Onyx platform, which targets a $1.5B market. Gross profit rose 13.7% to $44.2M, with gross margin at 79.3%. Net loss narrowed to $3.6M. The company reaffirmed 2026 revenue guidance of $231M-$233M and expects Q4 momentum from physician growth and new products.

finance.yahoo.com